Philip Hampton to step down as Glaxo CEO ahead of split
In December, CEO Emma Walmsley noted a plan to split Glaxo into two units: one for prescription drugs and vaccines, the other for OTC products
Bengaluru — GlaxoSmithKline chair Philip Hampton will step down after more than three-and-a-half years in the role, as Britain's biggest drug maker prepares to split its business into two. The announcement comes a month after Glaxo's CEO, Emma Walmsley, announced her boldest plans yet — to split the company into two businesses — one for prescription drugs and vaccines, the other for over-the-counter products. Walmsley, who took the helm in 2017, announced in December that Glaxo and Pfizer would combine their consumer health businesses in a joint venture with sales of £9.8bn, 68%-owned by the British company, in an all-equity transaction. "Following the announcement of our deal with Pfizer and the intended separation of the new consumer business, I believe this is the right moment to step down and allow a new chair to oversee this process through to its conclusion over the next few years," Hampton said in a statement. Hampton was paid a sum of £700,000, of which he elected to take 25...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.